The meta-analysis of 12 studies demonstrated a significant association between beta-blocker (BB) use and elevated PD-L1 expression (OR = 1.29, 95% CI: 1.10–1.52; I2 = 45%), indicative of enhanced tumor immunogenicity. This evidence concerns the gene CD274 and neoplasm.